腫瘍内癌治療市場は、腫瘍溶解性ウイルス療法のブレークスルーにより、2034年まで31.3%のCAGRで大きく拡大すると予測されています | DelveInsight

Intratumoral Cancer Therapies Market Poised for Significant Expansion with a 31.3% CAGR Through 2034, Fueled by Breakthroughs in Oncolytic Viral Therapy | DelveInsight

Intratumoral Cancer Therapies Market Insights, Epidemiology, and Market Forecast – 2034

The market for intratumoral cancer therapies is experiencing swift growth, propelled by increasing cancer rates, cutting-edge oncolytic viral treatments, and pioneering immunotherapy strategies from leading pharmaceutical companies such as Nanobiotix, Sirnaomics, Apexigen, Replimune, Merck, OncoSec Medical, Intensity Therapeutics, DNAtrix, Treovir, Philogen, Regeneron, Pfizer, BMS, Roche, Sanofi, Boehringer Ingelheim, Daiichi Sankyo, and more.

DelveInsight’s “Intratumoral Cancer Therapies Market Insights, Epidemiology, and Market Forecast – 2034” report offers a detailed examination of the intratumoral cancer therapies market, including historical and projected epidemiology data, along with market trends in the United States, EU4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan. It thoroughly assesses existing treatment methods, upcoming medications, market shares of specific therapies, and forecasts for the intratumoral cancer therapies market up to 2034, delivering essential information for stakeholders in the oncology field.

Per DelveInsight’s assessment, the intratumoral cancer therapies market is anticipated to grow rapidly at a 31.3% CAGR from 2020 to 2034 across the 7MM, spurred by the expected launch of new treatments capable of converting “cold tumors” into “hot tumors,” enabling the immune system to attack cancer cells more effectively. Additionally, the United States is projected to hold the largest portion of the intratumoral cancer therapy market.

Access the Intratumoral Cancer Therapies Market report to learn about the driving forces behind the therapeutic market @ Intratumoral Cancer Therapies Market Trends.

Based on DelveInsight’s projections, the overall number of intratumoral cancer patients in the 7MM reached 3.3 million in 2024, with expectations of substantial increases in the coming years.

The DelveInsight report segments intratumoral cancer therapies into categories such as total cases of selected indications, indication-specific target patient pools for intratumoral cancer therapies, and indication-specific treated cases of intratumoral cancer therapies.

Explore shifting patterns in Intratumoral Cancer Therapies patient pool predictions @ Intratumoral Cancer Therapies Epidemiology Analysis.

Intratumoral immunotherapy is emerging as a precise cancer treatment method, providing localized immune stimulation with fewer widespread side effects. The initial approved treatment in this area, Amgen’s IMLYGIC (T-Vec), gained US FDA approval for inoperable melanoma and European approval in 2015. Despite its novel strategy, IMLYGIC faced commercial hurdles due to modest survival improvements and rivalry from immune checkpoint inhibitors. Further progress includes Nanobiotix’s HENSIFY (NBTXR3), approved in Europe for soft tissue sarcoma, and Japan’s provisional approval of DELYTACT (G47∆) for malignant glioma, representing a major advancement in oncolytic viral therapies.

As per the DelveInsight report, the intratumoral cancer therapies pipeline is expanding quickly, with numerous promising drugs nearing regulatory approvals. Replimune’s primary candidate RP1 (vusolimogene oderparepvec), built on a proprietary Herpes Simplex Virus (HSV) platform, earned FDA Breakthrough Therapy Designation in November 2024 when combined with Bristol Myers Squibb’s nivolumab for advanced melanoma. Philogen, partnering with Sun Pharmaceutical, secured EMA validation of its Marketing Authorization Application (MAA) in July 2024 for Nidlegy (L19IL2 + L19TNF), an innovative skin cancer treatment. Candel Therapeutics is gearing up for a Biologics License Application (BLA) filing by Q4 2026 for CAN-2409, an adenoviral immunotherapy aimed at prostate cancer.

Additional innovators include Lytix Biopharma and Verrica Pharmaceuticals with LTX-315 (VP-315), CEL-SCI with MULTIKINE, Highlight Therapeutics with BO-112, Cytovation ASA with CY-101, Intensity Therapeutics with INT230-6, Ascendis Pharma with TransCon IL-2 β⁄γ, Treovir and Matica Biotechnology with G207, QBiotics with Tigilanol tiglate, NanOlogy with NanoPac, EpicentRx with AdAPT-001, and Medicenna Therapeutics with Bizaxofusp (MDNA55). As these advanced therapies progress, they are poised to transform intratumoral cancer care, introducing fresh options and elevating standards in oncology.

In early 2025, key updates highlighted the increasing dynamism in the intratumoral cancer therapies market. In March, Nanobiotix (EPA:NANO) shared preliminary outcomes from the dose-escalation phase of a Phase I study testing JNJ-1900 (NBTXR3), enhanced by radiation therapy, as a second-line or later option for advanced NSCLC in patients suitable for re-irradiation. That month, Nanobiotix also revised its global partnership with Janssen Pharmaceutical, eliminating its funding duties for the NANORAY-312 trial and forfeiting certain future milestone payments from Johnson & Johnson, while retaining potential for substantial future earnings.

In the same month, Candel Therapeutics (NASDAQ:CADL) formed a strategic commercial alliance with IDEA Pharma to aid the development and marketing of CAN-2409. In January 2025, Lokon Pharma AB obtained Fast Track Designation (FTD) from the FDA for LOAd703, its therapy for pancreatic cancer. Concurrently, Intensity Therapeutics (NASDAQ:INTS) reported that its Data Monitoring Committee (DMC) endorsed continuing its Phase III sarcoma trial (INVINCIBLE-3) for INT230-6, following positive data from July to December.

Learn about the latest progress in Intratumoral Cancer Therapies treatment options @ Intratumoral Cancer Therapies Recent Developments.

The intratumoral cancer therapies market is intensely competitive, featuring prominent entities like Nanobiotix (EPA:NANO), Sirnaomics (HKEX:2257), Apexigen (NASDAQ:APGN), Replimune (NASDAQ:REPL), Merck & Co (NYSE:MRK), Highlight Therapeutics, OncoSec Medical (NASDAQ:ONCS), Intensity Therapeutics (NASDAQ:INTS), DNAtrix, Treovir, Philogen, Lokon Pharma AB, Regeneron (NASDAQ:REGN), Istari Oncology, Pfizer (NYSE:PFE), Bristol-Myers Squibb (NYSE:BMY), Biogen (NASDAQ:BIIB), Immunovative Therapeutics, Idera Pharmaceuticals, Roche (SWX:ROG), Sanofi (EPA:SAN), Boehringer Ingelheim, and Daiichi Sankyo (TYO:4568), all pursuing varied approaches through strong R&D and partnerships. Among these, several Japanese, Korean, and Taiwanese companies are actively involved in clinical trials for intratumoral therapies, including:

Oncolys BioPharma : Drug candidate OBP-301 (Telomelysin) in Phase 1/2 trials; MOA involves oncolytic adenovirus for telomerase-expressing cancer cells; latest data from 2023 shows safety and efficacy in HNSCC (Trial ID: NCT03190824).

Takara Bio : Drug candidate HSV-1716 (Seprehvir) in Phase 1 trials; MOA is oncolytic HSV-1 for selective cancer cell destruction; completed trials with safety data in glioma (Trial ID: NCT02031965).

Daiichi Sankyo: Drug candidate DS-8201 in Phase 1/2 combo trials; MOA as antibody-drug conjugate; 2023 data shows enhanced responses in HER2-positive cancers (Trial ID: NCT03734029).

SillaJen : Drug candidate Pexa-Vec (JX-594) in Phase 3 trials; MOA involves oncolytic vaccinia virus with GM-CSF; 2019 Phase 3 data for HCC showed survival benefits (Trial ID: NCT02562755).

Helixmith : Drug candidate VM202 (Engensis) in Phase 2/3 trials; MOA uses plasmid DNA for HGF/IGF-1 delivery; 2023 data indicates reduced progression in pancreatic cancer (Trial ID: NCT03166878).

Green Cross LabCell : Drug candidate Immuncell-LC in Phase 1/2 trials; MOA as autologous dendritic cell vaccine; 2022 data shows immune activation in solid tumors (Trial ID: NCT01373554).

Highlight Therapeutics : Drug candidate BO-112 in Phase 1/2 trials; MOA activates TLR3/RIG-I for immune responses; 2023 data enhances PD-1 synergy (Trial ID: NCT02828098).

Medigen Vaccine Biologics : Drug candidate MVC-COV1901 in Phase 1 exploratory trials; MOA as protein subunit vaccine; 2023 safety data in solid tumors (Trial ID: NCT04783311).

Looking ahead, the intratumoral cancer therapies market is set for ongoing innovation, supported by progress in early detection tools, AI integration in cancer diagnosis, and tailored medicine. The growing cancer burden, with over 1.95 million new diagnoses in 2023, is boosting market expansion. Upcoming treatments targeting new pathways, such as oncolytic viruses, immune modulators, and genetic methods, offer hope for filling treatment gaps and reshaping care.

DelveInsight’s evaluation highlights that, amid existing treatment challenges, there are ample prospects for creating more potent, precise therapies that deliver lasting results and better survival rates for cancer patients globally. With accelerating research and adapting regulations, the intratumoral cancer therapies market is ready for substantial growth and medical innovations by 2034.

Table of Contents

1. Key Insights
2. Report Introduction
3. Executive Summary
4. Intratumoral Cancer Therapies Market Overview at a Glance
5. Epidemiology and Market Forecast Methodology
6. Key Events
7. Intratumoral Cancer Therapies Background and Overview
8. Intratumoral Cancer Therapies Treatment
9. Intratumoral Cancer Therapies Epidemiology and Patient Population in the 7MM
10. Intratumoral Cancer Therapies Patient Journey
11. Intratumoral Cancer Therapies Marketed Drug
12. Intratumoral Cancer Therapies Emerging Drugs
13. Intratumoral Cancer Therapies: 7MM Analysis
14. Unmet needs
15. SWOT Analysis
16. KOL Views
17. Market Access and Reimbursement
18. Appendix
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Related Reports 

Intratumoral Cancer Therapies - Epidemiology Forecast 2034

DelveInsight's "Intratumoral cancer therapies- Epidemiology Forecast-2034" report delivers an in-depth understanding of the intratumoral cancer therapies, historical and forecasted epidemiology as well as the intratumoral cancer therapies trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

Intra-tumoral Cancer Therapies Market Insights, Epidemiology, and Market Forecast 2034

DeveInsight’s “Intra-Tumoral Cancer Therapies Treatment Market Insights, Epidemiology, and Market Forecast – 2034” report delivers an in-depth understanding of Intra-Tumoral Cancer Therapies, historical and forecasted epidemiology as well as Intra-Tumoral Cancer Therapies market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.The leading Intratumoral Cancer Therapies Companies such as Merck, Istari Oncology, Replimune, Regeneron, Philogen, and others.

About DelveInsight

DelveInsight is a premier market research and advisory company focused on condition-specific intelligence and therapeutic market evaluations. Their reports blend real-world data, clinical trial results, and expert discussions to provide thorough industry knowledge.

Media Contact

Company Name: DelveInsight Business Research LLP

Contact Person: Kanishk Kumar

Email: kkumar@delveinsight.com 

Phone: 09650213330

Address: 304 S. Jones Blvd #2432

City: Las Vegas

State: NV

Country: United States

Website: https://www.delveinsight.com/